MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Revenue of MoonLake Immunotherapeutics (MLTX)
Revenue in 2023 (TTM): $
According to MoonLake Immunotherapeutics's latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of MoonLake Immunotherapeutics
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-13,158 | $-54,109,938 | $-43,984,729 | $-36,007,260 |
| 2022 | $ | $-12,358 | $-65,061,417 | $-64,469,685 | $-64,506,051 |
| 2021 | $ | $-4,971 | $-53,572,040 | $-53,638,860 | $-53,643,615 |
| 2020 | $ | $ | $-105,760 | $-90,838 | $-90,838 |